0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > PD-1 > Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag

Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™

  • Synonym
    PDCD1,PD1,CD279,SLEB2
  • Source
    Biotinylated Human PD-1, Fc,Avitag (PD1-H82F1) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).
    Predicted N-terminus: Leu 25
  • Molecular Characterization
    Online(Leu 25 - Gln 167) Q15116-1

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).

    The protein has a calculated MW of 44.4 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by reduced SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) SDS-PAGE gel

Biotinylated Human PD-1, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Biotinylated Human PD-1, Fc,AvitagBiotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) ELISA bioactivity

Immobilized Human PD-L1, Fc Tag (Cat. No. PD1-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) with a linear range of 20-320 ng/mL (QC tested).

Biotinylated Human PD-1, Fc,AvitagBiotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) ELISA bioactivity

Immobilized Nivolumab at 2 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) with a linear range of 0.2-6 ng/mL (Routinely tested).

Biotinylated Human PD-1, Fc,AvitagBiotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) ELISA bioactivity

Immobilized Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.2 μg/well) plate, can bind Mouse PD-L2, His Tag (Cat. No. PD2-M52E3) with a linear range of 20-156 ng/mL (Routinely tested).

Biotinylated Human PD-1, Fc,AvitagBiotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) ELISA bioactivity

Serial dilutions of nivolumab were added into Human PD-L1, Mouse IgG1 Fc Tag, low endotoxin (HPLC-verified) (Cat. No. PD1-H52A3): Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.3789 μg/mL (Routinely tested).

Biotinylated Human PD-1, Fc,AvitagBiotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) ELISA bioactivity

Serial dilutions of nivolumab were added into Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5): Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.2823 μg/mL (Routinely tested).

Comments (0)

Order Details

Price(USD) : $385.00

Price(USD) : $1518.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:6 Details
  • Number of Drugs in Clinical Trials:75 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop